Form 4: Voyager Therapeutics Director Nancy Vitale Acquires 24,000 Stock Options

Director Nancy Vitale acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Summary

• On June 5, 2024, Nancy Vitale, a director of Voyager Therapeutics, Inc., acquired 24,000 stock options.
• The options have an exercise price of $8.70.
• These options were granted under the company's 2015 Stock Option and Incentive Plan as part of the director compensation policy.
• The options vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service as a director.
• The options expire on June 5, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard stock option grant to a director, which is a routine corporate event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options, are typically benchmarked against peer companies in the biotechnology industry to attract and retain qualified board members.
• The vesting schedule and exercise price of these options would be compared to similar grants at comparable companies to ensure competitiveness.

Key Dates